Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 3.4.21.B10 - neurosin

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
Evaluation of human tissue kallikrein-related peptidases 6 and 10 expression in early gastroesophageal adenocarcinoma.
Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma.
Adenoma
Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma.
Alzheimer Disease
Accumulation of ?-synuclein in dementia with Lewy bodies is associated with decline in the ?-synuclein-degrading enzymes kallikrein-6 and calpain-1.
Assessment of kallikrein 6 as a cross-sectional and longitudinal biomarker for Alzheimer's disease.
Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease.
Decreased concentration of human kallikrein 6 in brain extracts of Alzheimer's disease patients.
Human kallikrein 6 as a biomarker of alzheimer's disease.
Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia.
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
One round of SELEX for the generation of DNA aptamers directed against KLK6.
Plasmatic level of neurosin predicts outcome of mild cognitive impairment.
Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin.
Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions.
Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
Astrocytoma
Prognostic significance of multiple kallikreins in high-grade astrocytoma.
Barrett Esophagus
Evaluation of human tissue kallikrein-related peptidases 6 and 10 expression in early gastroesophageal adenocarcinoma.
Brain Injuries, Traumatic
Kallikrein-related peptidase 6: a biomarker for traumatic brain injury in the rat.
Brain Neoplasms
Prognostic impact of CD68 and kallikrein 6 in human glioma.
Breast Neoplasms
A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
An integrated cell line-based discovery strategy identified follistatin and kallikrein 6 as serum biomarker candidates of breast carcinoma.
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.
Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.
Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer.
Carcinogenesis
Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.
Carcinoma
Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression.
Differential roles of kallikrein-related peptidase 6 in malignant transformation and ?Np63?-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma.
Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Human kallikrein 6 (zyme/protease M/neurosin): a new serum biomarker of ovarian carcinoma.
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.
Kallikrein-related peptidase 6 (KLK6) expression in the progression of colon adenoma to carcinoma.
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
Carcinoma, Endometrioid
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Carcinoma, Non-Small-Cell Lung
High Kallikrein-Related Peptidase 6 in Non-Small Cell Lung Cancer Cells: an indicator of tumor proliferation and poor prognosis.
Carcinoma, Ovarian Epithelial
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
Carcinoma, Squamous Cell
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
Chickenpox
Kallikrein-6-Regulated Pathways Shed Light on New Potential Targets in Varicella Zoster Virus Infection.
Colonic Neoplasms
Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.
Specific microRNA-mRNA Regulatory Network of Colon Cancer Invasion Mediated by Tissue Kallikrein-Related Peptidase 6.
Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.
Colorectal Neoplasms
Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer.
Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.
Lymph node tissue kallikrein-related peptidase 6 mRNA: a progression marker for colorectal cancer.
Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.
Dementia
A brain-targeted, modified neurosin (kallikrein-6) reduces ?-synuclein accumulation in a mouse model of multiple system atrophy.
Accumulation of ?-synuclein in dementia with Lewy bodies is associated with decline in the ?-synuclein-degrading enzymes kallikrein-6 and calpain-1.
Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type ?-Synuclein and Reduces the Pathology in an ?-Synuclein Model of LBD.
Low CSF levels of both ?-synuclein and the ?-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
Plasmatic level of neurosin predicts outcome of mild cognitive impairment.
The role of human kallikrein 6, clusterin and adiponectin as potential blood biomarkers of dementia.
Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
Dementia, Vascular
Kallikrein-related peptidase 6 in Alzheimer's disease and vascular dementia.
Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
Demyelinating Diseases
Activity of human kallikrein-related peptidase 6 (KLK6) on substrates containing sequences of basic amino acids. Is it a processing protease?
Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system.
Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease.
Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis.
Kallikrein-related peptidase 6: a biomarker for traumatic brain injury in the rat.
Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects.
Encephalomyelitis
In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins.
Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis.
Encephalomyelitis, Autoimmune, Experimental
In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins.
Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis.
Endometriosis
CD44, TGM2 and EpCAM as novel plasma markers in endometrial cancer diagnosis.
Glioblastoma
Clinical significance and novel mechanism of action of kallikrein 6 in glioblastoma.
Glioma
Prognostic impact of CD68 and kallikrein 6 in human glioma.
Herpes Zoster
Kallikrein-6-Regulated Pathways Shed Light on New Potential Targets in Varicella Zoster Virus Infection.
Laryngeal Neoplasms
Identification of human tissue kallikrein 6 as a potential marker of laryngeal cancer based on the relevant secretory/releasing protein database.
Lung Neoplasms
Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor.
High Kallikrein-Related Peptidase 6 in Non-Small Cell Lung Cancer Cells: an indicator of tumor proliferation and poor prognosis.
Melanoma
Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Expression and Function of the Kallikrein-Related Peptidase 6 in the Human Melanoma Microenvironment.
Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.
Multiple Sclerosis
Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response.
Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis.
Kallikrein 6 Regulates Early CNS Demyelination in a Viral Model of Multiple Sclerosis.
Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis.
Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions.
Multiple System Atrophy
A brain-targeted, modified neurosin (kallikrein-6) reduces ?-synuclein accumulation in a mouse model of multiple system atrophy.
Exploring the putative role of kallikrein-6, calpain-1 and cathepsin-D in the proteolytic degradation of ?-synuclein in multiple system atrophy.
Neoplasm Metastasis
Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.
Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.
Neoplasm, Residual
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.
Neoplasms
A potent, proteolysis-resistant inhibitor of kallikrein-related peptidase 6 (KLK6) for cancer therapy, developed by combinatorial engineering.
A tumor-protective role for human kallikrein-related peptidase 6 in breast cancer mediated by inhibition of epithelial-to-mesenchymal transition.
Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis.
Caveolin-1-mediated expression and secretion of kallikrein 6 in colon cancer cells.
Characterisation of human kallikrein 6/protease M expression in ovarian cancer.
Cloning and characterization of novel isoforms of the human kallikrein 6 gene.
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Development of Monoclonal Antibodies and Characterization of an ELISA Platform Against Kallikrein-Related Peptidase 6 as a Tumor Biomarker.
Effects of a phytoestrogen-containing soy extract on the growth-inhibitory activity of ICI 182 780 in an experimental model of estrogen-dependent breast cancer.
Expression and Function of the Kallikrein-Related Peptidase 6 in the Human Melanoma Microenvironment.
Expression of Kallikrein-Related Peptidase 6 in Primary Mucosal Malignant Melanoma of the Head and Neck.
Growth and survival of lung cancer cells: regulation by kallikrein-related peptidase 6 via activation of proteinase-activated receptor 2 and the epidermal growth factor receptor.
High Kallikrein-Related Peptidase 6 in Non-Small Cell Lung Cancer Cells: an indicator of tumor proliferation and poor prognosis.
Higher expression of human kallikrein 10 in breast cancer tissue predicts tamoxifen resistance.
Human kallikrein 6 degrades extracellular matrix proteins and may enhance the metastatic potential of tumour cells.
Human kallikrein 6 expression in salivary gland tumors.
Human kallikrein 6: a new potential serum biomarker for uterine serous papillary cancer.
Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates.
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.
Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism.
Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells.
Kallikrein 6 protease advances colon tumorigenesis via induction of the high mobility group A2 protein.
Kallikrein-related peptidase 6 (KLK6) expression differentiates tumor subtypes and predicts clinical outcome in breast cancer patients.
Kallikrein-related peptidase 6 (KLK6)gene expression in intracranial tumors.
Kallikrein-Related Peptidase 6 Is Associated with the Tumour Microenvironment of Pancreatic Ductal Adenocarcinoma.
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
KLK6 and KLK13 predict tumor recurrence in epithelial ovarian carcinoma.
KLK6 protease accelerates skin tumor formation and progression.
Lack of stimulatory activity of a phytoestrogen-containing soy extract on the growth of breast cancer tumors in mice.
Molecular Pathways Associated with Kallikrein 6 Overexpression in Colorectal Cancer.
Multiple mechanisms underlie the aberrant expression of the human kallikrein 6 gene in breast cancer.
One round of SELEX for the generation of DNA aptamers directed against KLK6.
Prognostic impact of CD68 and kallikrein 6 in human glioma.
Reference intervals and biological variation for kallikrein 6: influence of age and renal failure.
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis.
Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.
The structure of human prokallikrein 6 reveals a novel activation mechanism for the kallikrein family.
Up-regulation and clinical significance of serine protease kallikrein 6 in colon cancer.
Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.
Neurobehavioral Manifestations
Value of measuring plasmatic levels of neurosin in the diagnosis of Alzheimer's disease.
Neurodegenerative Diseases
Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism.
One round of SELEX for the generation of DNA aptamers directed against KLK6.
Reference intervals and biological variation for kallikrein 6: influence of age and renal failure.
Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions.
Neuroinflammatory Diseases
Kallikrein-related peptidase 6: a biomarker for traumatic brain injury in the rat.
Nevus
Cell adhesion and communication proteins are differentially expressed in melanoma progression model.
Ovarian Neoplasms
Characterisation of human kallikrein 6/protease M expression in ovarian cancer.
Clinical relevance of kallikrein-related peptidase 6 (KLK6) and 8 (KLK8) mRNA expression in advanced serous ovarian cancer.
Cloning and characterization of novel isoforms of the human kallikrein 6 gene.
Copy number and expression alterations of miRNAs in the ovarian cancer cell line OVCAR-3: impact on kallikrein 6 protein expression.
Diagnostic value of KLK6 as an ovarian cancer biomarker: A meta-analysis.
Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system.
Human kallikrein 6 activity is regulated via an autoproteolytic mechanism of activation/inactivation.
Identification and analysis of mammalian KLK6 orthologue genes for prediction of physiological substrates.
Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new independent unfavourable prognostic biomarker.
Potential markers that complement expression of CA125 in epithelial ovarian cancer.
Prognostic value of kallikrein-related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA).
Purification of human kallikrein 6 from biological fluids and identification of its complex with alpha(1)-antichymotrypsin.
Separation of kallikrein 6 glycoprotein subpopulations in biological fluids by anion-exchange chromatography coupled to ELISA and identification by mass spectrometry.
Stromal cell-associated expression of kallikrein-related peptidase 6 (KLK6) indicates poor prognosis of ovarian cancer patients.
Transcriptional upregulation of human tissue kallikrein 6 in ovarian cancer: clinical and mechanistic aspects.
Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Parkinson Disease
A brain-targeted, modified neurosin (kallikrein-6) reduces ?-synuclein accumulation in a mouse model of multiple system atrophy.
Cleavage of normal and pathological forms of alpha-synuclein by neurosin in vitro.
Extracellular neurosin degrades alpha-synuclein in cultured cells.
Lentivirus Mediated Delivery of Neurosin Promotes Clearance of Wild-type ?-Synuclein and Reduces the Pathology in an ?-Synuclein Model of LBD.
Localization of a novel type trypsin-like serine protease, neurosin, in brain tissues of Alzheimer's disease and Parkinson's disease.
Low CSF levels of both ?-synuclein and the ?-synuclein cleaving enzyme neurosin in patients with synucleinopathy.
Trypsin and trypsin-like proteases in the brain: proteolysis and cellular functions.
Peripheral Nervous System Diseases
Decreased cerebrospinal fluid levels of neurosin (KLK6), an aging-related protease, as a possible new risk factor for Alzheimer's disease.
Prostatic Neoplasms
Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.
RE: Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer.
Renal Insufficiency
Reference intervals and biological variation for kallikrein 6: influence of age and renal failure.
Skin Neoplasms
KLK6 protease accelerates skin tumor formation and progression.
Spinal Cord Injuries
Dynamic role of kallikrein 6 in traumatic spinal cord injury.
In vivo analysis of kallikrein-related peptidase 6 (KLK6) function in oligodendrocyte development and the expression of myelin proteins.
Squamous Cell Carcinoma of Head and Neck
Differential roles of kallikrein-related peptidase 6 in malignant transformation and ?Np63?-mediated epithelial-mesenchymal transition of oral squamous cell carcinoma.
Kallikrein-related peptidase 6 regulates epithelial-to-mesenchymal transition and serves as prognostic biomarker for head and neck squamous cell carcinoma patients.
Stomach Neoplasms
Clinicopathologic and biological significance of kallikrein 6 overexpression in human gastric cancer.
Correlation of hK6 expression with tumor recurrence and prognosis in advanced gastric cancer.
Expression and biological significance of human kallikrein 6 in gastric cancer tissues.
Kallikrein-related peptidase 6 induces chemotherapeutic resistance by attenuating auranofin-induced cell death through activation of autophagy in gastric cancer.
Silencing of kallikrein-related peptidase 6 attenuates the proliferation, migration, and invasion of gastric cancer cells through inhibition of epithelial-mesenchymal transition.
Upregulation and secretion of kallikrein-related peptidase 6 (KLK6) in gastric cancer.
Stomach Ulcer
Expression and biological significance of human kallikrein 6 in gastric cancer tissues.
Subarachnoid Hemorrhage
Kallikrein 6 as a serum prognostic marker in patients with aneurysmal subarachnoid hemorrhage.
Synucleinopathies
Alpha-synuclein degradation by serine protease neurosin: implication for pathogenesis of synucleinopathies.
Low CSF levels of both ?-synuclein and the ?-synuclein cleaving enzyme neurosin in patients with synucleinopathy.